newsfilter
← Latest News
GlobeNewswire·

SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • Tvardi shares plummeted over 80% on Monday, October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101.
  • The study, designed to assess safety & exploratory outcomes for idiopathic pulmonary fibrosis, did not meet its goals regarding lung function changes.
  • Preliminary data showed baseline characteristics were similar across arms, except percent predicted FVC was lower in placebo-treated patients compared to TTI-101-treated arms.
  • Investors with significant losses in Tvardi stock or options are encouraged to contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • Additional information regarding the investigation is available at www.faruqilaw.com/TVRD.